Biocycle | News

Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn’s disease patients stopping infliximab.

10 janvier 2023

ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease.

A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.

An inflammatory serum metabolomic signature predicts response to vedolizumab treatment in people with Crohn’s Disease.

19 septembre 2022

Report from IIS Award Winner 2021 : Nicolas Pierre.

Stopping Anti-TNF in Crohn’s Disease Remitters: Pros and Cons: The Pros.

Presentation JFHOD2022

Oral presentations ECCO 2022

3 février 2022

News from Biocycle

1